As space exploration becomes increasingly accessible, understanding the molecular and pathophysiological consequences of spaceflight on the human body becomes crucial. Space-induced modifications could disrupt multiple signaling pathways, with significant implications for the functional integrity of cardiovascular, nervous, and musculoskeletal systems, among others. In a recent study, Bourdakou et al. have focused on alterations in gene expression profiles linked to cardiovascular disease (CVD), using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) undergoing spaceflight and subsequent postflight conditions. Genes with known associations with CVD and nuclear factor erythroid 2-related factor 2 (NRF2) oxidative stress regulatory network have been identified to present consistent directional expression changes in both spaceflight and postflight. A computational drug repurposing analysis identified ten candidate agents with the potential to reverse observed transcriptomic modifications in spaceflight-exposed cardiomyocytes. These findings highlight the importance of molecular studies and emphasize the need for integrative, multi-omic research efforts to protect human health during and beyond spaceflight.
{"title":"Beyond Gravity: Leveraging Gene Plasticity to Mitigate Spaceflight-Induced Pathologies","authors":"Irina-Mihaela Matache","doi":"10.1002/pmic.202500087","DOIUrl":"10.1002/pmic.202500087","url":null,"abstract":"<p>As space exploration becomes increasingly accessible, understanding the molecular and pathophysiological consequences of spaceflight on the human body becomes crucial. Space-induced modifications could disrupt multiple signaling pathways, with significant implications for the functional integrity of cardiovascular, nervous, and musculoskeletal systems, among others. In a recent study, Bourdakou et al. have focused on alterations in gene expression profiles linked to cardiovascular disease (CVD), using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) undergoing spaceflight and subsequent postflight conditions. Genes with known associations with CVD and nuclear factor erythroid 2-related factor 2 (NRF2) oxidative stress regulatory network have been identified to present consistent directional expression changes in both spaceflight and postflight. A computational drug repurposing analysis identified ten candidate agents with the potential to reverse observed transcriptomic modifications in spaceflight-exposed cardiomyocytes. These findings highlight the importance of molecular studies and emphasize the need for integrative, multi-omic research efforts to protect human health during and beyond spaceflight.</p>","PeriodicalId":224,"journal":{"name":"Proteomics","volume":"25 11-12","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pmic.202500087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144503147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>We are living in an omics era, in which molecular profiling technologies can detect thousands of molecules across multiple biological layers. Yet chronic diseases—such as chronic kidney disease (CKD) and cardiovascular disease (CVD)—are still diagnosed only after overt signs and symptoms appear, relying on biomarkers that indicate established organ damage (e.g., estimated glomerular filtration rate (eGFR), albuminuria, troponin T, natriuretic peptides) [<span>1</span>]. In other words, by the time a chronic disease is recognized, curative treatment is generally no longer possible, as irreversible organ damage has already occurred. These conditions are termed “chronic” because, once they develop, patients live with them for the rest of their lives. Additionally, their life expectancy is shorter with a significant loss of quality of life.</p><p>Preventive measures to reduce the global burden of chronic diseases are therefore of paramount importance. The impact is enormous: in 2021, CKD caused 1.5 million deaths [<span>2</span>], while CVD accounted for more than 20 million deaths [<span>3</span>], with ischemic heart disease the leading and CKD the eleventh leading cause of mortality worldwide. Disability-adjusted life-years (DALYs) totaled 212 million for ischemic heart disease and 44.5 million for CKD [<span>4</span>]. In addition, the economic impact of both CKD and CVD is huge and is estimated to further increase in the coming years [<span>5-7</span>]. However, diagnosed cases represent only the “tip of the iceberg” (Figure 1); most patients remain undiagnosed because these diseases develop silently and progressively over the years.</p><p>CKD and CVD originate at the molecular level (bottom of the iceberg), are tightly interconnected—each increasing the risk of the other—and share common risk factors such as diabetes and hypertension. Additionally, therapies overlap for example, in patients with established CKD, renin–angiotensin system inhibitors, sodium-glucose co-transporter 2 inhibitors, and the non-steroidal mineralocorticoid receptor agonist finerenone reduce not only the risk of kidney disease progression but also cardiovascular events [<span>3</span>]. Considering the continuum of disease development, it is logical to intervene as early as possible, when the disease-associated changes are only at the molecular level. Moreover, early intervention has been demonstrated to be the most effective approach. In fact, intervention before irreversible organ damage should ideally even prevent onset of chronic disease. At the same time, no single biomarker can capture the complexity of these systemic disorders, which involve multiple organs and show marked heterogeneity in progression and treatment response. The societal, healthcare, and economic burden of CKD and CVD underscores the need for personalized, omics-based approaches that accommodate this multifactorial complexity and enable personalized intervention.</p><p>Personalized medicine rep
{"title":"Multi-Disciplinary and Omics-Driven Approaches to Advance Personalized Medicine in Cardiovascular and Chronic Kidney Disease","authors":"Griet Glorieux, Julie Klein, Agnieszka Latosinska","doi":"10.1002/pmic.202500093","DOIUrl":"10.1002/pmic.202500093","url":null,"abstract":"<p>We are living in an omics era, in which molecular profiling technologies can detect thousands of molecules across multiple biological layers. Yet chronic diseases—such as chronic kidney disease (CKD) and cardiovascular disease (CVD)—are still diagnosed only after overt signs and symptoms appear, relying on biomarkers that indicate established organ damage (e.g., estimated glomerular filtration rate (eGFR), albuminuria, troponin T, natriuretic peptides) [<span>1</span>]. In other words, by the time a chronic disease is recognized, curative treatment is generally no longer possible, as irreversible organ damage has already occurred. These conditions are termed “chronic” because, once they develop, patients live with them for the rest of their lives. Additionally, their life expectancy is shorter with a significant loss of quality of life.</p><p>Preventive measures to reduce the global burden of chronic diseases are therefore of paramount importance. The impact is enormous: in 2021, CKD caused 1.5 million deaths [<span>2</span>], while CVD accounted for more than 20 million deaths [<span>3</span>], with ischemic heart disease the leading and CKD the eleventh leading cause of mortality worldwide. Disability-adjusted life-years (DALYs) totaled 212 million for ischemic heart disease and 44.5 million for CKD [<span>4</span>]. In addition, the economic impact of both CKD and CVD is huge and is estimated to further increase in the coming years [<span>5-7</span>]. However, diagnosed cases represent only the “tip of the iceberg” (Figure 1); most patients remain undiagnosed because these diseases develop silently and progressively over the years.</p><p>CKD and CVD originate at the molecular level (bottom of the iceberg), are tightly interconnected—each increasing the risk of the other—and share common risk factors such as diabetes and hypertension. Additionally, therapies overlap for example, in patients with established CKD, renin–angiotensin system inhibitors, sodium-glucose co-transporter 2 inhibitors, and the non-steroidal mineralocorticoid receptor agonist finerenone reduce not only the risk of kidney disease progression but also cardiovascular events [<span>3</span>]. Considering the continuum of disease development, it is logical to intervene as early as possible, when the disease-associated changes are only at the molecular level. Moreover, early intervention has been demonstrated to be the most effective approach. In fact, intervention before irreversible organ damage should ideally even prevent onset of chronic disease. At the same time, no single biomarker can capture the complexity of these systemic disorders, which involve multiple organs and show marked heterogeneity in progression and treatment response. The societal, healthcare, and economic burden of CKD and CVD underscores the need for personalized, omics-based approaches that accommodate this multifactorial complexity and enable personalized intervention.</p><p>Personalized medicine rep","PeriodicalId":224,"journal":{"name":"Proteomics","volume":"25 11-12","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pmic.202500093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144503146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Motahare Khorrami, Paul A. Haynes, Christopher Pastras, Mohsen Asadnia
The cochlea, an incredibly sensitive sensory system, detects sound waves and converts them into electrical signals the brain recognizes as sound. Damage to cochlear hair cells can release proteins, triggering biological responses that may impair hearing. Mass spectrometry-based proteomics offers insights into protein expression changes in cochlear tissues, improving our understanding of inner ear diseases. In this study, we performed a comprehensive proteomics analysis of whole cochlear tissue extracted from healthy guinea pigs and rats. The study optimized protein extraction protocols and analyzed cochlear protein expression using three biological replicates for each animal model. The results included the identification of 1841 proteins in guinea pigs and 3423 proteins in rats, with a high overlap in cochlear protein expression between the left and right ears—93% in guinea pigs and 89% in rats. The findings validate the assumption that the cochlear tissues from both sides of the ears can be considered biologically equivalent. This experiment provides a comprehensive cochlear proteome for guinea pigs and rats, supporting future studies on inner ear disorders.
{"title":"Quantitative Proteomics of Cochlear Tissues: Bilateral Comparisons in Guinea Pigs and Rats","authors":"Motahare Khorrami, Paul A. Haynes, Christopher Pastras, Mohsen Asadnia","doi":"10.1002/pmic.13977","DOIUrl":"10.1002/pmic.13977","url":null,"abstract":"<p>The cochlea, an incredibly sensitive sensory system, detects sound waves and converts them into electrical signals the brain recognizes as sound. Damage to cochlear hair cells can release proteins, triggering biological responses that may impair hearing. Mass spectrometry-based proteomics offers insights into protein expression changes in cochlear tissues, improving our understanding of inner ear diseases. In this study, we performed a comprehensive proteomics analysis of whole cochlear tissue extracted from healthy guinea pigs and rats. The study optimized protein extraction protocols and analyzed cochlear protein expression using three biological replicates for each animal model. The results included the identification of 1841 proteins in guinea pigs and 3423 proteins in rats, with a high overlap in cochlear protein expression between the left and right ears—93% in guinea pigs and 89% in rats. The findings validate the assumption that the cochlear tissues from both sides of the ears can be considered biologically equivalent. This experiment provides a comprehensive cochlear proteome for guinea pigs and rats, supporting future studies on inner ear disorders.</p>","PeriodicalId":224,"journal":{"name":"Proteomics","volume":"25 13","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pmic.13977","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren E. Grubb, Mohana Talasila, Linda Y. Gorim, Richard Glen Uhrig
Increasing global food production demands have resulted in increased fertilizer usage, causing detrimental environmental impacts. Biostimulants, such as humic substances, are currently being applied as a strategy to increase plant nutrient-use efficiency and minimize environmental impacts within cropping systems. One of these biostimulants is Humalite, which is a unique, naturally occurring coal-like substance found in deposits across southern Alberta. These deposits contain exceptionally high ratios of humic acids (>70%) and micronutrients due to their unique freshwater depositional environment. Humalite has begun to be applied to fields based on scientific data suggesting positive impacts on crop growth, yield, and nutrient usage; however, little is known about the underlying molecular mechanisms of Humalite. Here, as part of a larger field study, we report a quantitative proteomics approach to identify systems-level molecular changes induced by the addition of different Humalite application rates in field-grown wheat (Triticum aestivum L.) under three urea fertilizer application rates. In particular, we see wide-ranging abundance changes in proteins associated with several metabolic pathways and growth-related biological processes that suggest how Humalite modulates the plant molecular landscape. Overall, our results provide new, functional information that will help better inform agricultural producers on optimal biostimulant and fertilizer usage.
{"title":"Defining the Molecular Impacts of Humalite Application on Field-Grown Wheat (Triticum aestivum L.) Using Quantitative Proteomics","authors":"Lauren E. Grubb, Mohana Talasila, Linda Y. Gorim, Richard Glen Uhrig","doi":"10.1002/pmic.13981","DOIUrl":"10.1002/pmic.13981","url":null,"abstract":"<p>Increasing global food production demands have resulted in increased fertilizer usage, causing detrimental environmental impacts. Biostimulants, such as humic substances, are currently being applied as a strategy to increase plant nutrient-use efficiency and minimize environmental impacts within cropping systems. One of these biostimulants is Humalite, which is a unique, naturally occurring coal-like substance found in deposits across southern Alberta. These deposits contain exceptionally high ratios of humic acids (>70%) and micronutrients due to their unique freshwater depositional environment. Humalite has begun to be applied to fields based on scientific data suggesting positive impacts on crop growth, yield, and nutrient usage; however, little is known about the underlying molecular mechanisms of Humalite. Here, as part of a larger field study, we report a quantitative proteomics approach to identify systems-level molecular changes induced by the addition of different Humalite application rates in field-grown wheat (<i>Triticum aestivum</i> L.) under three urea fertilizer application rates. In particular, we see wide-ranging abundance changes in proteins associated with several metabolic pathways and growth-related biological processes that suggest how Humalite modulates the plant molecular landscape. Overall, our results provide new, functional information that will help better inform agricultural producers on optimal biostimulant and fertilizer usage.</p>","PeriodicalId":224,"journal":{"name":"Proteomics","volume":"25 14","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pmic.13981","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}